KER 047
Alternative Names: KER-047Latest Information Update: 08 Dec 2023
Price :
$50 *
At a glance
- Originator Massachusetts General Hospital; National Center for Advancing Translational Sciences
- Developer Keros Therapeutics
- Class Antianaemics; Small molecules
- Mechanism of Action ACVR1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anaemia; Fibrodysplasia ossificans progressiva; Iron deficiency anaemia
Most Recent Events
- 21 Nov 2023 Keros Therapeutics withdraws a phase II trial in Iron deficiency anaemia in Israel, Australia (PO) (NCT05927012) due to recruitment challenges (NCT05927012)
- 06 Nov 2023 Discontinued - Phase-I for Anaemia in USA (PO) (Keros Therapeutics pipeline, January 2024)
- 06 Nov 2023 Discontinued - Phase-I for Fibrodysplasia ossificans progressiva (In volunteers) in Australia (PO) (Keros Therapeutics pipeline, January 2024)